Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Garg, Gunjal ^a   Vangveravong, Suwanna ^a   Zeng, Chenbo ^b   Collins, Lynne ^c   Hornick, Mary ^a   Hashim, Yassar ^a   Piwnica Worms, David ^c,d   Powell, Matthew A ^a   Mutch, David G ^a   Mach, Robert H ^b   Hawkins, William G ^a   Spitzer, Dirk ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Drug conjugate; Ovarian cancer; Sigma 2 ligand; SMAC peptidomimetic; Small molecule; Targeted drug delivery

Indexed keywords

ANTINEOPLASTIC AGENT; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SIGMA 2 OPIATE RECEPTOR; SW IV 134; SW IV 52; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL DEATH; CONJUGATION; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PROTEIN DEGRADATION; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT;

INTRACISTERNAL A-PARTICLES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZABICYCLO COMPOUNDS; BIOMIMETIC MATERIALS; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROGRAFTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MICE; MICE, SCID; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RECEPTORS, SIGMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84899654324     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-50     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Canc J Clin 2013, 63:11-30.
2. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Canc Inst 2003, 95:1320-1329. Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
3. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008, 5:194-204.
4. Steller H. Mechanisms and genes of cellular suicide. Science 1995, 267:1445-1449. 10.1126/science.7878463, 7878463.
5. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462. 10.1126/science.7878464, 7878464.
6. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 12:1543-1568. 10.1007/s10495-007-0087-3, 17573556.
7. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53. 10.1016/S0092-8674(00)00009-X, 10929712.
8. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, Wang L. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010, 17:1645-1654. 10.1038/cdd.2010.44, 3104849, 20431601.
9. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N, Sun H, Williams N, Minna JD, Brekken RA. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Canc Res 2010, 70:2852-2861.
10. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Canc Biol Ther 2010, 10:885-892.
11. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 2004, 305:1471-1474. 10.1126/science.1098231, 15353805.
12. Kashiwagi H, McDunn JE, Simon PO, Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH, Hawkins WG. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Canc 2007, 6:48.
13. Zeng C, Rothfuss J, Zhang J, Chu W, Vangveravong S, Tu Z, Pan F, Chang KC, Hotchkiss R, Mach RH. Sigma-2 ligands induce tumour cell death by multiple signalling pathways. Br J Canc 2012, 106:693-701.
14. Spitzer D, Simon PO, Kashiwagi H, Xu J, Zeng C, Vangveravong S, Zhou D, Chang K, McDunn JE, Hornick JR, Goedegebuure P, Hotchkiss RS, Mach RH, Hawkins WG. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Canc Res 2012, 72:201-209.
15. Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Canc 2010, 9:298.
16. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS, Hawkins WG, Wheeler KT, Mach RH. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011, 2:380. 3624020, 21730960.
17. Mach RH, Wheeler KT. Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo. Cent Nerv Syst Agents Med Chem 2009, 9:230-245. 10.2174/1871524910909030230, 2802455, 20021357.
18. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Canc Res 1997, 57:156-161.
19. Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, Shen D, Zhuang ZP, Kung HF, Mach RH. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Canc Res 2007, 67:6708-6716.
20. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H, Fesik SW. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004, 47:4417-4426. 10.1021/jm040037k, 15317454.
21. Zeng C, Vangveravong S, Jones LA, Hyrc K, Chang KC, Xu J, Rothfuss JM, Goldberg MP, Hotchkiss RS, Mach RH. Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Mol Imaging 2011, 10:420-433.
22. Hornick JR, Vangveravong S, Spitzer D, Abate C, Berardi F, Goedegebuure P, Mach RH, Hawkins WG. Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J Exp Clin Canc Res 2012, 31:41.
23. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997, 326(Pt 1):1-16. 1218630, 9337844.
24. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992, 148:2207-2216.
25. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42. 10.1016/S0092-8674(00)00008-8, 10929711.
26. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681. 10.1016/j.cell.2007.10.030, 18022362.
27. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Canc 2000, 82:1223-1232.
28. Vucic D. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr Canc Drug Targets 2008, 8:110-117.
29. Yang QH, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem 2004, 279:16963-16970. 10.1074/jbc.M401253200, 14960576.
30. Varfolomeev E, Vucic D. (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 2008, 7:1511-1521. 10.4161/cc.7.11.5959, 18469528.
31. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004, 18:2195-2224. 10.1101/gad.1228704, 15371334.
32. Scheidereit C. IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 2006, 25:6685-6705. 10.1038/sj.onc.1209934, 17072322.
33. Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005, 30:43-52. 10.1016/j.tibs.2004.11.009, 15653325.
34. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499. 10.1126/science.1062677, 11520989.
35. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell 2001, 7:401-409. 10.1016/S1097-2765(01)00187-3, 11239468.
36. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004, 10:1032-1042. 10.1016/j.ymthe.2004.08.013, 15564135.
37. Dehdashti F, Laforest R, Gao F, Shoghi KI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnston N, Mach RH. Assessment of cellular proliferation in tumors by PET using 18 F-ISO-1. J Nucl Med 2013, 54:350-357. 10.2967/jnumed.112.111948, 3694753, 23359657.
38. Zobel K, Wang L, Varfolomeev E, Franklin MC, Elliott LO, Wallweber HJ, Okawa DC, Flygare JA, Vucic D, Fairbrother WJ, Deshayes K. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem Biol 2006, 1:525-533. 10.1021/cb600276q, 17168540.
39. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, Bolognesi M, Anichini A, Kashkar H, Walczak H, Delia D. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Canc 2010, 102:1707-1716.
40. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Canc Res 2007, 67:10976-10983.
41. Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Canc Discov 2013, 3:212-223.
42. Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg Med Chem 2006, 14:6988-6997. 10.1016/j.bmc.2006.06.028, 16837201.
43. Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Canc Res 2007, 13:5001-5009.
44. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Meth 2005, 2:607-614.